Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC
Introduction - Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324). - Methods - In this multicenter, open-label phase 1a/b trial, patients received ramucirumab 10 mg/kg and pembrolizumab 200 mg every 21...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
Journal of thoracic oncology
Year: 2021, Jahrgang: 16, Heft: 2, Pages: 289-298 |
| ISSN: | 1556-1380 |
| DOI: | 10.1016/j.jtho.2020.10.004 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2020.10.004 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086420308091 
|
| Verfasserangaben: | Roy S. Herbst, MD, PhD, Hendrik Tobias Arkenau, MD, Johanna Bendell, MD, Edward Arrowsmith, MD, Martin Wermke, MD, Andres Soriano, MD, Nicolas Penel, MD, Rafael Santana-Davila, MD, Helge Bischoff, MD, Ian Chau, MD, Gu Mi, PhD, Hong Wang, PhD, Erik Rasmussen, PhD, David Ferry, MD, Bo H. Chao, MD, Luis Paz-Ares, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1757702806 | ||
| 003 | DE-627 | ||
| 005 | 20240413193350.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210512s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtho.2020.10.004 |2 doi | |
| 035 | |a (DE-627)1757702806 | ||
| 035 | |a (DE-599)KXP1757702806 | ||
| 035 | |a (OCoLC)1341408840 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Herbst, Roy S. |d 1963- |e VerfasserIn |0 (DE-588)1233388584 |0 (DE-627)1757737111 |4 aut | |
| 245 | 1 | 0 | |a Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC |c Roy S. Herbst, MD, PhD, Hendrik Tobias Arkenau, MD, Johanna Bendell, MD, Edward Arrowsmith, MD, Martin Wermke, MD, Andres Soriano, MD, Nicolas Penel, MD, Rafael Santana-Davila, MD, Helge Bischoff, MD, Ian Chau, MD, Gu Mi, PhD, Hong Wang, PhD, Erik Rasmussen, PhD, David Ferry, MD, Bo H. Chao, MD, Luis Paz-Ares, MD |
| 246 | 3 | 0 | |a one |
| 264 | 1 | |c 2021 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 15 October 2020 | ||
| 500 | |a Gesehen am 12.05.2021 | ||
| 520 | |a Introduction - Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324). - Methods - In this multicenter, open-label phase 1a/b trial, patients received ramucirumab 10 mg/kg and pembrolizumab 200 mg every 21 days for up to 35 cycles. PD-L1 positivity was defined as tumor proportion score (TPS) greater than or equal to 1%. Exploratory NanoString biomarker analyses included three T-cell signatures (T-cell-inflamed, Gajewski, and effector T cells) and CD274 gene expression. - Results - Cohort E included 26 patients. Treatment-related adverse events of any grade occurred in 22 patients (84.6%). Treatment-related adverse events of grade greater than or equal to 3 were reported in 11 patients (42.3%); the most frequent was hypertension (n = 4, 15.4%). Objective response rate was 42.3% in the treated population and 56.3% and 22.2% for patients with high (TPS ≥ 50%) and lower levels (TPS 1%-49%) of PD-L1 expression, respectively. Median progression-free survival (PFS) in the treated population was 9.3 months, and 12-month and 18-month PFS rates were 45% each. Median PFS was not reached in patients with PD-L1 TPS greater than or equal to 50% and was 4.2 months in patients with PD-L1 TPS 1% to 49%. Median overall survival was not reached in the treated population, and 12-month and 18-month overall survival rates were 73% and 64%, respectively. Biomarker data suggested a positive association among clinical response, three T-cell signatures, CD274 gene expression, and PD-L1 immunohistochemistry. - Conclusions - First-line therapy with ramucirumab plus pembrolizumab has a manageable safety profile in patients with NSCLC, and the efficacy signal seems to be strongest in tumors with high PD-L1 expression. | ||
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a Ramucirumab | |
| 650 | 4 | |a Treatment-naive | |
| 700 | 1 | |a Arkenau, Hendrik Tobias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bendell, Johanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arrowsmith, Edward |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wermke, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soriano, Andres |e VerfasserIn |4 aut | |
| 700 | 1 | |a Penel, Nicolas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Santana-Davila, Rafael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bischoff, Helge |d 1958- |e VerfasserIn |0 (DE-588)111184576 |0 (DE-627)389658286 |0 (DE-576)167287249 |4 aut | |
| 700 | 1 | |a Chau, Ian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mi, Gu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Hong |e VerfasserIn |0 (DE-588)1085674320 |0 (DE-627)848976495 |0 (DE-576)45705011X |4 aut | |
| 700 | 1 | |a Rasmussen, Erik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferry, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chao, Bo H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paz-Ares, Luis |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology |d Amsterdam : Elsevier, 2006 |g 16(2021), 2, Seite 289-298 |h Online-Ressource |w (DE-627)508331986 |w (DE-600)2223437-8 |w (DE-576)336961553 |x 1556-1380 |7 nnas |a Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:2 |g pages:289-298 |g extent:11 |a Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jtho.2020.10.004 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1556086420308091 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210512 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 111184576 |a Bischoff, Helge |m 111184576:Bischoff, Helge |d 910000 |d 950000 |d 950900 |e 910000PB111184576 |e 950000PB111184576 |e 950900PB111184576 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 9 | ||
| 999 | |a KXP-PPN1757702806 |e 392761176X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"2021"}],"person":[{"given":"Roy S.","role":"aut","family":"Herbst","display":"Herbst, Roy S."},{"display":"Arkenau, Hendrik Tobias","role":"aut","given":"Hendrik Tobias","family":"Arkenau"},{"display":"Bendell, Johanna","family":"Bendell","given":"Johanna","role":"aut"},{"display":"Arrowsmith, Edward","role":"aut","given":"Edward","family":"Arrowsmith"},{"display":"Wermke, Martin","given":"Martin","role":"aut","family":"Wermke"},{"given":"Andres","role":"aut","family":"Soriano","display":"Soriano, Andres"},{"display":"Penel, Nicolas","family":"Penel","given":"Nicolas","role":"aut"},{"given":"Rafael","role":"aut","family":"Santana-Davila","display":"Santana-Davila, Rafael"},{"display":"Bischoff, Helge","given":"Helge","role":"aut","family":"Bischoff"},{"family":"Chau","given":"Ian","role":"aut","display":"Chau, Ian"},{"display":"Mi, Gu","family":"Mi","role":"aut","given":"Gu"},{"display":"Wang, Hong","role":"aut","given":"Hong","family":"Wang"},{"display":"Rasmussen, Erik","role":"aut","given":"Erik","family":"Rasmussen"},{"display":"Ferry, David","family":"Ferry","role":"aut","given":"David"},{"role":"aut","given":"Bo H.","family":"Chao","display":"Chao, Bo H."},{"family":"Paz-Ares","role":"aut","given":"Luis","display":"Paz-Ares, Luis"}],"relHost":[{"disp":"Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLCJournal of thoracic oncology","recId":"508331986","physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"2","extent":"11","text":"16(2021), 2, Seite 289-298","pages":"289-298","volume":"16","year":"2021"},"title":[{"title":"Journal of thoracic oncology","title_sort":"Journal of thoracic oncology","subtitle":"JTO ; official publication of the International Association for the Study of Lung Cancer"}],"id":{"eki":["508331986"],"issn":["1556-1380"],"zdb":["2223437-8"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"JTO"}],"pubHistory":["1.2006 -"],"origin":[{"dateIssuedKey":"2006","dateIssuedDisp":"2006-","publisherPlace":"Amsterdam ; Philadelphia, Pa.","publisher":"Elsevier ; Lippincott Williams & Wilkins"}]}],"title":[{"title_sort":"Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC","title":"Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Available online 15 October 2020","Gesehen am 12.05.2021"],"recId":"1757702806","physDesc":[{"extent":"11 S."}],"name":{"displayForm":["Roy S. Herbst, MD, PhD, Hendrik Tobias Arkenau, MD, Johanna Bendell, MD, Edward Arrowsmith, MD, Martin Wermke, MD, Andres Soriano, MD, Nicolas Penel, MD, Rafael Santana-Davila, MD, Helge Bischoff, MD, Ian Chau, MD, Gu Mi, PhD, Hong Wang, PhD, Erik Rasmussen, PhD, David Ferry, MD, Bo H. Chao, MD, Luis Paz-Ares, MD"]},"id":{"doi":["10.1016/j.jtho.2020.10.004"],"eki":["1757702806"]}} | ||
| SRT | |a HERBSTROYSPHASE1EXPA2021 | ||